Background: Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data from the primary analysis of a phase 2 study of daratumumab monotherapy in relapsed or refractory (R/R) NKTCL. Methods: This phase 2 study with Simon's two-stage design evaluated daratumumab in patients with histologically confirmed extranodal NKTCL, nasal type, per WHO classification that was refractory to or relapsed after ≥ 1 line of chemotherapy, who were not candidates for other treatment modalities. All patients received daratumumab 16 mg/kg intravenously once weekly for Cycles 1 and 2, every other week for Cycles 3 thr...
Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the im...
PURPOSE: On the basis of the benefits of frontline radiation in early-stage, extranodal, natural kil...
Abstract Background Extranodal natural killer/T-cell lymphoma (NKTCL), nasal type, is an aggressive ...
Background The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL...
Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-li...
Purpose: To explore a more effective treatment for newly diagnosed stage IV, relapsed, or refractory...
BACKGROUND: Daratumumab is a CD38 monoclonal antibody approved for treating relapsed/refractory and ...
International audienceABSTRACT: BACKGROUND: Extranodal nasal-type NK/T-cell lymphoma is a rare and s...
Introduction: There are a number of regimens used to treat relapsed/refractory aggressive lymphoma...
This international, multicentre phase II study was conducted to assess ofatumumab, a human anti-CD20...
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer...
Abstract Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase...
The efficacy/tolerability of bendamustine, a unique alkylator, plus ofatumumab, a human anti-CD20 mo...
Objectives: The aim of this study is to compare the toxicity profiles of SMILE versus less intense L...
Purpose: Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with malignant cells that ...
Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the im...
PURPOSE: On the basis of the benefits of frontline radiation in early-stage, extranodal, natural kil...
Abstract Background Extranodal natural killer/T-cell lymphoma (NKTCL), nasal type, is an aggressive ...
Background The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL...
Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-li...
Purpose: To explore a more effective treatment for newly diagnosed stage IV, relapsed, or refractory...
BACKGROUND: Daratumumab is a CD38 monoclonal antibody approved for treating relapsed/refractory and ...
International audienceABSTRACT: BACKGROUND: Extranodal nasal-type NK/T-cell lymphoma is a rare and s...
Introduction: There are a number of regimens used to treat relapsed/refractory aggressive lymphoma...
This international, multicentre phase II study was conducted to assess ofatumumab, a human anti-CD20...
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer...
Abstract Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase...
The efficacy/tolerability of bendamustine, a unique alkylator, plus ofatumumab, a human anti-CD20 mo...
Objectives: The aim of this study is to compare the toxicity profiles of SMILE versus less intense L...
Purpose: Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with malignant cells that ...
Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the im...
PURPOSE: On the basis of the benefits of frontline radiation in early-stage, extranodal, natural kil...
Abstract Background Extranodal natural killer/T-cell lymphoma (NKTCL), nasal type, is an aggressive ...